This is an alarm in the Netherlands. Eleven children died after their mother, pregnant, took Viagra as part of a scholarly research that the blue pill, used against erectile dysfunction in men, would strengthen deformed placenta and promote fetal growth . . The result is that women involved in pharmaceutical experimentation "are now living their pregnancy with extreme anxiety". As reported in Guardian research, conducted in 10 hospitals in the Netherlands, involved some expectant mothers who presented with placental complications that, along with other drugs, sildenafil, known commercially as name of Viagra. The famous blue pill has the fundamental function of dilating the blood vessels and is used to combat erectile dysfunction in men and in people with high blood pressure. The experiment, conducted previously on mice, was aimed at using this drug to increase blood flow through the placenta, promoting the growth of the child. However, the test was blocked after an external committee overseeing the research found that many children were born with lung problems.
A total of 93 women received the drug in the trial, led by Amsterdam. University Medical Center. Seventeen children developed lung problems and 11 died. Another 90 women were followed as a control group, giving them a placebo: only 3 children developed lung problems here and none died. Between 10 and 15 women are waiting to find out if their child has been hit. Fifteen women have not yet given birth and their greatest concern is that their children develop lung problems. In fact, the drugs may have caused hypertension in the lungs, with the consequence that the children had too little oxygen. There is no suggestion that the research was poorly managed. In an interview with the Dutch newspaper De Volkskrant the director of research, the gynecologist Wessel Ganzevoort, still admits the defeat: "We wanted to prove that there is an effective way to promote the growth of l & # 39; 39; child. the opposite: I am shocked. The last thing we would like to do is harm patients. "
